沙利度胺联合三维适形放射治疗中晚期肝癌  

Effect of Three Dimensional Conformal Radiation Therapy Combined with Thalidomide on Advanced Hepatic Carcinoma

作　　者：陈明聪 钱水章[2] 何桂芬[2] 蒋先明 刘树勋 吴海波 

机构地区：[1]浙江省温岭市第二人民医院肿瘤内科,温岭317502 [2]上海复旦大学附属肿瘤医院放疗科,上海200032

出　　处：《中国中西医结合外科杂志》2010年第1期17-19,共3页Chinese Journal of Surgery of Integrated Traditional and Western Medicine

基　　金：温岭市科技局资助[WL2006(53)]

摘　　要：目的:探讨沙利度胺(TLD)联合三维适形放射(3-DCRT)治疗中晚期原发性肝癌的临床疗效及不良反应。方法:60例患者分观察组和对照组各30例,观察组在3-DCRT基础上加口服TLD,对照组不用TLD。结果:近期疗效显示观察组肿瘤完全缓解(CR)4例,部分缓解(PR)22例,无变化(NC)3例,进展(PD)1例,总有效率为86.7%(P<0.05)。两组未见严重不良反应发生。随访3年,观察组1、2、3年生存率分别为73.3%、56.7%、36.7%;对照组为46.7%、30.0%、13.3%(P<0.05)。结论:应用TLD与3-DCRT联合治疗中晚期原发性肝癌疗效明显,不良反应轻,具有一定的临床应用价值。Objective To observe the effect of three dimensional conformal radiation therapy（3-DCRT） combined with thalidomide（TLI） on advanced hepatic carcinoma. Methods Sixty advanced hepatic carcinoma patients were assigned to 2 groups. TLD group were treated by 3-DCRT combined with TLD, and control group were only treated by 3-DCRT. The main outcome measure was the response rate and toxin response： secondary outcome was the overall survival rate. Results The overall response rate was 86.7% in the TLD group and 63.3% in the control group （P〈0.05）. There was no severely side-effect in both groups. The overall 1,2,3-year survival rate were 73.3%,56.7% and 36.7% respectively in the TLD group, and 46.7%,30.0% and 13.3% respectively in the control group. There were significant difference of the 2- and 3-year survival rates between the two groups （P〈0.05）. Conclusion Combined thalidomide with 3-DCRT is more effective than 3-DCRT alone for the advanced hepatocellular carcinoma. The adverse effects are tolerable, so the combined therapy has certain value for clinical application.

关 键 词：原发性肝癌 沙利度胺 三维适形放射治疗 

分 类 号：R737.7[医药卫生—肿瘤]